Novavax, Inc. NVAX announced that it has modified the existing agreement with the Serum Institute of India Private Limited (SIIPL), the world’s largest vaccine development under which it will also manufacture the antigenic component of Novavax’s COVID-19 candidate vaccine, NVX- CoV2373Array As a result of this new development, the company is expanding its candidate vaccine production capacity to more than two billion doses in line with the year , when it is at full capacity until mid-2021.
In August 2020, Novavax signed a licensing agreement with SIIPL for the progression and marketing of NVX-CoV2373 in low- and middle-income countries (PRFI) and India. The agreement is expected to reach at least one billion doses of NVX-CoV2373 for India. low- and middle-income countries. Under the pact, Novavax intended to supply the vaccine antigen and matrix M adjuvant to SIIPL. However, with the above amendment, SIIPL will now also manufacture the antigenic component of NVX-CoV2373.
Novavax shares rose 4. 3% on Tuesday after the inventory mentioned above, in fact, inventory has soared 2,672. 3% so far this year to the industry’s 1. 3% increase.
The NVX-CoV2373 is Novavax’s patented nanoparticle generation and includes its exclusive Matrix M adjuvant. The candidate vaccine is recently being evaluated in Phase II studies after an initial level examination showed that NVX-CoV2373 was sometimes well tolerated and produced higher levels of antibodies opposed to the new coronavirus. The company plans to initiate phase III global efficacy studies on the same subject in the coming weeks.
Meanwhile, NVX-CoV2373 is manufactured through organizations/companies (manufacturing plants in partnership) worldwide, in addition to SIIPL in India, Biofabri in Spain, FUJIFILM Diosynth Biotechnologies (FDB) in the United States and United Kingdom, SK Bioscience in the Republic of Korea and Takeda Pharmaceutical in Japan are preparing the candidate vaccine.
In particular, Novavax acquired Praha Vaccines in the Czech Republic for approximately $167 million in money in May. The acquisition added a biological production plant in Bohumil, Czech Republic, which will likely provide an annual capacity of more than one billion doses of NVX. CoV2373 as of 2021 It is important to note that the antigenic component of NVX-CoV2373 is manufactured on this site.
Novavax is one of dozens of corporations that are developing a vaccine against deadly coronavirus disease Several giant corporations, such as AstraZeneca AZN/University of Oxford, Pfizer PFE, as well as his German wife BioNTech and Modern MRNA have already presented their Phase III studies in their respective COVID-19 candidate vaccines. In the current scenario, we are waiting for this race contrary to time to get approval of a possible COVID-19 vaccine that will be accentuated in the coming months.
Novavax currently uses a row of Zacks 3 (Keep). You can see the full list of existing Zacks 1 Rank moves here.
She may be the mother of all technological revolutions. Apple has sold only one billion iPhones in 10 years, but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1. 7 trillion market. Zacks has just published a special report highlighting this fast-onset phenomenon and 6 tickers to take advantage of it. If you don’t buy now, it can happen in 2021.
Click to see the 6 operations
Click to view this loose AstraZeneca PLC (AZN): Pfizer Inc. Free Inventory Analysis Report. (PFE): Modern, Inc. Free Inventory Analysis Report (MRNA): Novavax, Inc. Free Inventory Analysis Report (NVAX): Free Inventory Analysis Report To access this item in Zacks. com, click here.